Sirpiglenastat
Sirpiglenastat preferentially bioactivated to 6-Diazo-5-oxo-l-norleucine (DON derivative of Glutamine) in tumor while bioinactivated to an inert metabolite in gastro intestinal tissues. Sirpiglenastat induces antitumor efficacy through nntagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems
General
Type : Pro-Drug, Drug, Peptide
Chemical_Nomenclature : propan-2-yl (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoate
Canonical SMILES : CC(C)OC(=O)C(CCC(=O)C=[N+]=[N-])NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C
InChI : InChI=1S\/C22H27N5O5\/c1-13(2)32-22(31)19(9-8-16(29)12-25-23)27-21(30)20(26-14(3)28)10-15-11-24-18-7-5-4-6-17(15)18\/h4-7,11-13,19-20,24H,8-10H2,1-3H3,(H,26,28)(H,27,30)\/t19-,20-\/m0\/s1
InChIKey : LQNMCWOJACNQQM-PMACEKPBSA-N
Other name(s) : CHEMBL4650367 || SCHEMBL20465436 || (-)-sirpiglenastat || DRP-104 || Ac-Trp-Glu(Unk)-OiPr
MW : 441.5
Formula : C22H27N5O5
CAS_number : 2079939-05-0
PubChem : 137308771
UniChem : LQNMCWOJACNQQM-PMACEKPBSA-N
Target
Structures : No structure
Families : Carb_B_Chordata
References (2)
| Title : Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug - Rais_2022_Sci.Adv_8_eabq5925 |
| Author(s) : Rais R , Lemberg KM , Tenora L , Arwood ML , Pal A , Alt J , Wu Y , Lam J , Aguilar JMH , Zhao L , Peters DE , Tallon C , Pandey R , Thomas AG , Dash RP , Seiwert T , Majer P , Leone RD , Powell JD , Slusher BS |
| Ref : Sci Adv , 8 :eabq5925 , 2022 |
| Abstract : |
| PubMedSearch : Rais_2022_Sci.Adv_8_eabq5925 |
| PubMedID: 36383674 |
| Title : Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems - Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| Author(s) : Yokoyama Y , Estok TM , Wild R |
| Ref : Mol Cancer Ther , 21 :1561 , 2022 |
| Abstract : |
| PubMedSearch : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| PubMedID: 35930753 |